Novartis AG CEO Joe Jimenez

Novartis AG CEO Joe Jimenez

Simon Dawson/Bloomberg

Novartis AG's Afinitor U.S. approval for breast cancer could give Chief Executive Officer Joe Jimenez a welcome $1.5 billion sales boost just as some of the company’s top sellers lose patent protection, including the top-selling blood pressure pill Diovan and the cancer drug Gleevec.